COVID-19 Sample Collection Kits Market Size, Share & Trends Report

COVID-19 Sample Collection Kits Market Size, Share & Trends Analysis Report By Product (Swabs, Viral Transport Media), By Application, By Site Of Collection (Home Test, Hospitals & Clinics), By Region, And Segment Forecasts, 2020 - 2027

  • Published Date: May, 2020
  • Base Year for Estimate: 2020
  • Report ID: GVR-4-68038-539-7
  • Format: Electronic (PDF)
  • Historical Data: 2020
  • Number of Pages: 130

Report Overview

The global COVID-19 sample collection kits market size was valued at USD 2.8 billion in 2020 and is expected to grow at a compound annual growth rate (CAGR) of 4.9% from 2020 to 2027. An exponential rise in the number of COVID-19 cases and inadequate laboratory-based molecular testing capacity are factors that have encouraged several companies to develop rapid and easy-to-use tests, which boosts the market growth. Furthermore, approval of synthetic swabs for use in diagnosis of coronavirus infection and the subsequent increase in its production are expected to drive the market.

Canada COVID-19 sample collection kits market size

In April 2020, the Food and Drug Administration (FDA) approved the use of spun synthetic swabs that are similar to Q-tips swabs designed for COVID-19 testing. This approval allows patients to self-collect samples and minimize the potential exposure to healthcare professionals. Furthermore, U.S. Cotton, one of the key manufacturers of cotton swabs in U.S., is engaged in developing polyester swabs at a large scale to effectively address the growing need for COVID-19 diagnostic testing.

Collection of samples is the most vital step in the laboratory diagnosis of several infectious diseases including coronavirus infection. Improper and inaccurate sample collection may lead to false or negative test results. Therefore, the Centers for Disease Control and Prevention (CDC) has recommended a standard sample collection procedure for specimen collection and transport with regard to SARS-CoV-2 testing. These regulatory guidelines have helped in streamlining the usage of COVID-19 sample collection kits.

As COVID-19 diagnostic testing continues to scale-up, several studies are being conducted to investigate different sample collection approaches that yield accurate results. A research study found that saliva samples collected from patients with the infection provide better detection sensitivity and consistency than the widely-used nasopharyngeal approach. It was also observed that there was low variability in results obtained using saliva samples, which is expected to expand their penetration of this approach in future.

The COVID-19 outbreak has severely affected supplies of Viral Transport Media (VTM) due to high demand for SARS-CoV-2 RT-PCR testing worldwide. Governments of several countries as well as various companies are rapidly scaling-up VTM production to address the challenges in coronavirus testing. Recently, COPAN Diagnostics optimized its production line to fulfill the large volumes of orders. On the other hand, the Federal Emergency Management and FDA are working with various suppliers to address the demand for VTM.

Product Insights

The swabs segment is anticipated to lead the COVID-19 sample collection kits market and account for around 40.0% share in terms of revenue in 2020. The PCR technique, which involves the collection of genetic material using a Q-tip nasal swab, is regarded as a gold standard for COVID-19 testing. This, in turn, drives the adoption of different types of swabs at a large scale, resulting in maximum revenue share of the swabs segment.

Key companies have adopted several strategic models to accelerate the production and supply of swabs for COVID-19 testing, which drives the segment at a lucrative rate. For instance, in May 2020, Puritan Medical Group partnered with Bath Iron Works, the U.S. shipyard, to increase its swab production capacity by twofold. The latter company is manufacturing a wide array of specialized machines that help Puritan increase its swab production from 20 million to 40 million per month.

The VTM segment accounts for a significant revenue share, as this media is a key component in testing the presence of SARS-CoV-2 in individuals. Demand for VTM is continuously increasing with rise in the number of coronavirus cases. Furthermore, robust protocols recommended by WHO and CDC with regard to manufacture of VTM allow laboratories and institutes to boost their production and address the global shortage of VTM, thereby driving the segment.

Site of Collection Insights

Hospitals and clinics segment is estimated to account for the largest revenue share of 95.6% in 2020 due to increased need for testing of coronavirus infection in communities. Government and local regulatory bodies are engaged in enhancing patient admission capacities at hospitals, increasing the number of medical professionals, and making diagnostic tests and ventilators available for management of COVID-19 crisis. This is expected to result in a high sales volume of specimen collection solutions within hospital and clinical settings.

Moreover, with increase in the number of coronavirus cases, several private hospitals have geared up to tackle this crisis. For instance, an Indian chain of healthcare network, Max Healthcare, started admitting coronavirus-affected patients for quarantine since March 2020. It provides treatments in specially designated isolation wards. With this initiative, private hospitals aim at helping the government fight against the global pandemic, consequently driving the segment growth.

Global COVID-19 sample collection kits market share

Home test segment is expected to expand at the fastest CAGR with the FDA approval of first COVID-19 home test in April 2020. It enables the individual to collect a sample at home and prevent disease transmission. The Pixel by LabCorp is a real-time reverse transcription PCR test that detects the presence of SARS-CoV-2. This product approval is expected to provide lucrative opportunities for effective testing at home care settings.

Application Insights

The diagnostic application segment is expected to account for a maximum revenue share of 70.2% in 2020. This can be attributed to continuous approvals of molecular diagnostic tests for SARS-CoV-2. Various diagnostic tests have different requirements pertaining to swabs and transport media. For instance, DiaSorin S.p.A’s Simplexa COVID-19 Direct Test uses nasopharyngeal swabs in around 3 mL of BD Viral Transport Media or COPAN Universal Transport Media.

Supportive government regulations and investments to encourage the development of efficient COVID-19 diagnostic methods are expected to fuel the segment growth. As reported in March 2020, the United States Department of Health & Human Services (HHS) provided USD 598,000 to QIAGEN and USD 679,000 to DiaSorin Molecular for development of their respective diagnostic tests. Development of rapid diagnostic tests is expected to address the large-scale demand for COVID-19 testing.

The research segment accounts for a low penetration in the global market in terms of revenue generation. However, a number of research studies are being conducted to analyze the incidence rate and spread of coronavirus infection, examine the effectiveness of various diagnostic tests, and evaluate various transport mediums and swabs, which is expected to drive the segment growth. The availability of funds for research studies further boosts the revenue generation in this segment.

Regional Insights

Europe is estimated to dominate the market and account for around 35% revenue share in 2020. A large number of coronavirus cases in the European region along with high volume of swabs tested in Germany contribute to a large share. Germany leads other countries, such as U.K. and France, in terms of testing volume. In Germany, 132 laboratories carried out an average of 116,655 swab tests per day in the fourth week of April 2020, adding up to approximately 1.3 million tests. This high volume of testing assists the nation to slow down the spread of coronavirus and the associated death rate. The confluence of these factors results in high uptake of medical sterile swabs and specimen collection kits in Europe.

On the other hand, Asia Pacific is anticipated to witness lucrative growth over the forecast period due to efforts undertaken by home-grown companies to expand their offerings, such as introduction of improved sample collection kit by Singapore-based Lucence Diagnostics Pte Ltd in March 2020, to overcome the impact of COVID-19. In addition, government bodies have been proactive in disease management in the region. For instance, the Defense Research and Development Organization (DRDO) introduced COVSACK (COVID Sample Collection Kiosk), a COVID-19 sample collection booth, as a measure to mitigate the reliance of healthcare professionals on Personal Protection Equipment (PPEs), thereby driving the regional revenue share.

Key Companies & Market Share Insights

Key participants are constantly accelerating the production and supply of specimen collection kits. The volume of swabs arriving from COPAN Diagnostics, Italy, in U.S. is continuously increasing. Around 6 tons of swabs were imported in March 2020 and 4.5 tons of swabs in January 2020 from COPAN to the U.S. ports. On the other hand, Quest Diagnostics has distributed around 2 million swab collection kits in U.S. as reported until May 2020.

Moreover, a substantial number of companies from other domains are engaged in helping the government overcome the shortage of medical sterile swabs. As reported in May 2020, Royal DSM, a health, nutrition, and materials company, entered the swab manufacturing market to combat the shortage of specimen collection products in the Netherlands. This is the first time the company is generating swabs to meet the nation’s testing needs. The company is also donating 11 tons of material required for swab production in the country. Some of the prominent players in the COVID-19 sample collection kits market include:

  • Thermo Fisher Scientific, Inc.

  • Puritan Medical Products

  • COPAN Diagnostics

  • Becton, Dickinson and Company

  • Laboratory Corporation of America Holdings

  • Lucence Diagnostics Pte Ltd.

  • Hardy Diagnostics

  • BNTX Inc.

  • Formlabs

  • Medline Industries, Inc.

  • HiMedia Laboratories

  • VIRCELL S.L.

COVID-19 Sample Collection Kits Market Report Scope

Report Attribute

Details

Market size value in 2020

USD 2.8 billion

Revenue forecast in 2027

USD 3.9 billion

Growth Rate

CAGR of 4.9% from 2020 to 2027

Base year for estimation

2020

Historical data

2020 (as of April 2020)

Forecast period

2021 - 2027

Quantitative units

Revenue in USD Million and CAGR from 2020 to 2027

Report coverage

Revenue forecast, company ranking, competitive landscape, growth factors, and trends

Segments covered

Product, Application, Site of Collection, Region

Regional scope

North America; Europe; Asia Pacific; Latin America; Middle East & Africa

Country scope

U.S.; Canada; Germany; U.K.; France; Spain; Italy; China; India; Brazil; Mexico; South Africa

Key companies profiled

Thermo Fisher Scientific, Inc.; Puritan Medical Products; COPAN Diagnostics; Becton, Dickinson and Company; Laboratory Corporation of America Holdings; Lucence Diagnostics Pte Ltd.; Hardy Diagnostics; BNTX Inc.; Formlabs; Medline Industries, Inc.; HiMedia Laboratories; VIRCELL S.L.

Customization scope

Free report customization (equivalent up to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.

Pricing and purchase options

Avail customized purchase options to meet your exact research needs. Explore purchase options


Segments Covered in the Report

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2020 to 2027. For the purpose of this study & based on the data available as of April 2020, Grand View Research has segmented the global COVID-19 sample collection kits market report on the basis of product, application, site of collection, and region:

  • Product Outlook (Revenue, USD Million, 2020 - 2027)

    • Swabs

      • Nasopharyngeal (NP) swabs

      • Oropharyngeal (OP) swabs

      • Others

    • Viral Transport Media

    • Blood Collection Kits

    • Other Consumables

  • Application Outlook (Revenue, USD Million, 2020 - 2027)

    • Diagnostics

    • Research

  • Site of Collection Outlook (Revenue, USD Million, 2020 - 2027)

    • Hospitals & Clinics

    • Home Test

  • Regional Outlook (Revenue, USD Million, 2020 - 2027)

    • North America

      • U.S.

      • Canada

    • Europe

      • U.K.

      • Germany

      • France

      • Italy

      • Spain

    • Asia Pacific

      • China

      • India

    • Latin America

      • Brazil

      • Mexico

    • Middle East Africa (MEA)

      • South Africa

Frequently Asked Questions About This Report

Pricing & Purchase Options

Buy Chapters or Sections

Avail customized purchase options to meet your exact research needs:

  • Buy sections of this report
  • Buy country level reports
  • Request for historical data
  • Request discounts available for Start-Ups & Universities

Why Choose Us

  • Research support

    24/5 Research support

    Get your queries resolved from an industry expert.

  • Custom research service

    Custom research service

    Design an exclusive study to serve your research needs.

  • Quality assurance

    Quality assurance

    A testimonial for service in the form of BBB "A" Accreditation.

  • BBB Rating dandb
  • Information security

    Information security

    Your personal and confidential information is safe and secure.

  • grand view research PCI DSS complaint grand view research paypal verified